Safer Drinking Spaces Study (SDSS)

August 20, 2026 updated by: Marni Kan, RTI International

Rigorous Evaluation of Training in Alcohol-Serving Venues for Sexual Violence Prevention

The goal of this study is to evaluate the active bystander training provided by Safe Bars, Inc. and their local chapter organizations to staff at alcohol-serving establishments (e.g., bars). The training aims to improve norms about violence, create safer environments by teaching staff to intervene in potentially harmful situations, and help prevent sexual violence in the venue community. The study will examine the implementation and effectiveness of the training. The main questions it aims to answer are:

  1. Do staff and patrons at venues that have received Safe Bars training experience lower rates of sexual violence at the venue than staff and patrons at venues that have not received the training?
  2. Are staff at venues that have received Safe Bars training more likely to intervene in potentially risky situations than staff at venues that have not received the training?
  3. What characteristics of venue environments and staff and patron beliefs and perceptions are responsible for effects of the training on sexual violence and bystander behavior outcomes?
  4. What characteristics and conditions are necessary for effective Safe Bars implementation and improved staff and patron outcomes?

Researchers will compare staff and patron experiences at venues that have received the training with venues that are offered a delayed training. Staff and patron participants will be asked to complete surveys over about 12 months, research staff will conduct observations of training and observations in the venues, and selected venue managers and staff will be asked to complete individual interviews.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The prevalence of sexual violence (SV) is still unacceptably high in the United States and alcohol-serving venues (e.g., bars, nightclubs) are the most common public setting where SV occurs. Extensive research confirms that the venue environment, coupled with alcohol consumption, is associated with increased rates of SV. Trainings for venue staff, which combine bystander intervention skill-building with discussion of organization-level changes to policies, norms, and environmental characteristics, are a promising approach to prevent SV because they address both individual and community (i.e., venue)-level risk and protective factors. To date, these trainings have not been rigorously evaluated in terms of SV outcomes. There is a critical need to test the effectiveness of prevention approaches that change both individual behavior in venues and characteristics of venue settings to reduce SV among staff and patrons.

The proposed study will assess the effectiveness of Safe Bars active bystander training, which involves training and support for alcohol-serving venues, for primary prevention of SV. Safe Bars, Inc. has implemented trainings for venue staff since 2013, with 135 venues in 15 states trained either directly by Safe Bars, Inc. or by one of their trained chapter organizations since 2022. Grounded in established theories of behavior change, Safe Bars promotes anti-violence norms and creates safer environments by increasing bystander intervention among venue staff and generating venue-level solutions to preventing SV (such as improving policies or increasing anti-violence messaging in the venue).

In a prior study, the research team established the feasibility of evaluating venue-based SV prevention by conducting an evaluability assessment, including formative research and pilot testing of procedures. Informed by the results, the proposed evaluation uses a Hybrid Type 1 effectiveness-implementation design to assess the impact of Safe Bars training on SV among venue staff and patrons (Aim 1); examine venue environment characteristics, staff and patron psychosocial factors, and staff bystander intervention behaviors as mediators of Safe Bars training effects on SV outcomes (Aim 2); and examine potential moderating characteristics necessary for effective Safe Bars implementation and improved staff and patron outcomes (Aim 3). The study will use repeated surveys of patrons and staff at 15 intervention and 15 waitlist control venues, semi-structured interviews with managers and staff, training observations, venue observations, and Safe Bars implementation records to evaluate effectiveness and implementation and measure costs.

Safe Bars training is manualized for dissemination and has shown strong community acceptability. The outcomes of this study are expected to have an important positive impact by expanding the evidence base for community-level SV prevention and informing future implementation of venue-focused interventions.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
3180

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.
  • Name: Marni Kan
  • Phone Number: 919-485-2756
  • Email: mkan@rti.org

Study Contact Backup

Study Locations

  • United States
    • Arkansas
      • Little Rock, Arkansas, United States, 72204
        • Recruiting
        • University of Arkansas at Little Rock
        • Contact:
    • Florida
      • Gainesville, Florida, United States, 32611
        • Recruiting
        • University of Florida
        • Contact:
    • North Carolina
      • Durham, North Carolina, United States, 27713
        • Recruiting
        • RTI International
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • At least 18 years old
  • Able to read and speak English
  • Employee or patron of participating venues

Exclusion Criteria:

  • Has any condition that, in the opinion of the PI or their designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Safe Bars Training
Venues assigned to this arm will receive the Safe Bars active bystander training for their staff after baseline data collection for the study.
Behavioral: Safe Bars active bystander training
Safe Bars, Inc. (SBI)'s active bystander training is a primary prevention approach with three main components designed to (1) educate venue staff about the associations between alcohol and SV, (2) build bystander intervention skills and self-efficacy among venue staff, and (3) generate venue-level solutions to SV prevention. The 2.5-hour initial training combines didactic teaching with group brainstorming and practice-based role plays to teach staff actions they can take in response to risky scenarios observed in venue settings. Beyond increasing staff knowledge and skill, the training is also designed to spur venues' plans to support long-term culture change that reflects their local context and needs. After the initial training, SBI maintains a regular schedule of follow-up with trained venues to offer implementation support and access to SBI's other trainings in de-escalation and allyship.
Other: Wait-List Control
Venues assigned to this arm will be offered the Safe Bars active bystander training for their staff after the 6-month follow-up data collection for the study. They will not receive an intervention during the first 6 months of the study.
Behavioral: Safe Bars active bystander training
Safe Bars, Inc. (SBI)'s active bystander training is a primary prevention approach with three main components designed to (1) educate venue staff about the associations between alcohol and SV, (2) build bystander intervention skills and self-efficacy among venue staff, and (3) generate venue-level solutions to SV prevention. The 2.5-hour initial training combines didactic teaching with group brainstorming and practice-based role plays to teach staff actions they can take in response to risky scenarios observed in venue settings. Beyond increasing staff knowledge and skill, the training is also designed to spur venues' plans to support long-term culture change that reflects their local context and needs. After the initial training, SBI maintains a regular schedule of follow-up with trained venues to offer implementation support and access to SBI's other trainings in de-escalation and allyship.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Sexual assault victimization among patrons
Time Frame: Baseline to 12 months
Endorsement (yes) to any of 5 items asking about experiences in the past month at the venue
Baseline to 12 months
Sexual harassment victimization among patrons
Time Frame: Baseline to 12 months
Endorsement (yes) of any of 8 items asking about experiences in the past month at the venue
Baseline to 12 months
Sexual assault victimization among staff
Time Frame: Baseline to 12 months
Endorsement (yes) to any of 5 items asking about experiences in the past month at the venue
Baseline to 12 months
Sexual harassment victimization among staff
Time Frame: Baseline to 12 months
Endorsement (yes) of any of 8 items asking about experiences in the past month at the venue
Baseline to 12 months
Staff bystander behavior
Time Frame: Baseline to 6 months
Proportion of opportunities (out of 17 possible) in which staff reported that they intervened in a risky situation
Baseline to 6 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Staff acceptance of sexual violence
Time Frame: Baseline to 6 months
Average of 6 items on a 1-5 scale; higher scores indicate more acceptance
Baseline to 6 months
Staff self-efficacy to intervene
Time Frame: Baseline to 6 months
Average of 17 items on a 1-5 scale; higher scores indicate more self-efficacy
Baseline to 6 months
Staff perceived safety of the venue
Time Frame: Baseline to 6 months
Average of 5 items on a 1-5 scale; higher scores indicate less perceived safety
Baseline to 6 months
Patron perceived safety of the venue
Time Frame: Baseline to 6 months
Average of 5 items on a 1-5 scale; higher scores indicate less perceived safety
Baseline to 6 months
Patron witnessing venue staff intervention
Time Frame: Baseline to 6 months
Proportion of opportunities (out of 17 possible) in which patrons reported that they saw staff intervene in a risky situation
Baseline to 6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
RTI International

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
University of Florida
Centers for Disease Control and Prevention
University of Arkansas

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
August 13, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 7, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 7, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 14, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 24, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 20, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • U01CE003755 (U.S. NIH Grant/Contract)
  • 1U01CE003755-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Deidentified survey data from venue staff and patrons will be automatically archived after the study ends via the University of Florida's long-term electronic storage system, so it will be able to be made available to other researchers upon request with proper documentation of planned use and subsequent destruction. The data will be destroyed five years after the study ends. Participants' identifying information (names and contact information) will not be included in shared data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings